Sclerosis News and Research

RSS

Healthcare management application targeting MS patients released

A Pennsylvania-based company has just released a healthcare management application that targets Multiple Sclerosis (MS) patients to the App Store.

29 Dec 2009

TSC proteins regulate Notch activity

Two independent teams of researchers have identified a role for enhanced activation of the signaling protein Notch in tumors characterized by inactivation of either the TSC1 or the TSC2 protein. As indicated by Warren Pear, at the University of Pennsylvania, Philadelphia, in an accompanying commentary, these data provide a rationale for testing whether Notch inhibitors are of benefit to those with TSC-associated tumors.

29 Dec 2009

Nutrient-rich foods for weight loss

For the majority of Americans who are unhappy with their weight at any given moment, the New Year brings mixed emotions: the renewed resolution to shed pounds and the challenge of learning how to eat right to reach those goals.

29 Dec 2009

Senate health care bill will increase patient access and help create high-wage, high-value jobs

“These provisions mean increased access for the patients of today and renewed hope for the patients of tomorrow. In addition, they will help create high-wage, high-value jobs in our nation’s burgeoning biotech sector and help maintain U.S. global leadership in innovation.”

28 Dec 2009

Study reveals genomic switches separate autoimmune disorders in different clusters

Genomic switches can predispose an individual to one set of autoimmune disorders but protect the same person against another set of them, scientists at Stanford University School of Medicine have found.

24 Dec 2009

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.

23 Dec 2009

Researchers mix active drug and placebo to maximize drug benefits for efficient treatment

Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine.

23 Dec 2009

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

Neuralstem, Inc. today announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA.

19 Dec 2009

UAB professors honored for scientific contributions and outstanding mentorship

Three University of Alabama at Birmingham (UAB) professors have been elected fellows of the American Association for the Advancement of Science (AAAS).

18 Dec 2009

Opexa Therapeutics completes registered direct offering

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series

18 Dec 2009

People are more prone to Crohn's disease and ulcerative colitis, explains new research

New research by the University of Adelaide could help explain why some people are more prone to Crohn's disease, ulcerative colitis and other autoimmune diseases.

17 Dec 2009

EMD Serono, Brigham and Women's Hospital collaborate in MS research

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a strategic collaboration with Brigham and Women's Hospital in Boston, to advance basic and clinical research in multiple sclerosis (MS), with the goal of generating new and innovative discoveries that advance treatment for people living with this condition. The multi-faceted agreement will run for up to 5 years, with the potential to renew the alliance thereafter. Both parties decided not to disclose financial details.

16 Dec 2009

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Physical activity is known to reduce depression and fatigue in people struggling with chronic illness. A new study indicates that this effect stems from an individual's sense of mastery over - or belief in his or her ability to achieve - certain physical goals.

16 Dec 2009

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

The ALS Therapy Development Institute (ALS TDI) and Applied Proteomics, Inc. announced today that they have completed the first stage of a multi-year collaboration to identify and validate protein biomarkers associated with amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

15 Dec 2009

UT researchers identify new molecule that slows ALS progression in mice

Researchers at UT Southwestern Medical Center have found that a molecule produced naturally by muscles in response to nerve damage can reduce symptoms and prolong life in a mouse model of amyotrophic lateral sclerosis (ALS).

11 Dec 2009

microRNA-206 plays crucial role in the progression of ALS

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced the publication of data demonstrating that microRNA-206 (miR-206) plays a crucial role in the progression of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and in neuromuscular synaptic regeneration in mice.

11 Dec 2009

Prize4life partners with Jackson Laboratory on AML research

Prize4Life, an organization dedicated to finding a cure for amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), is partnering with The Jackson Laboratory to help more researchers identify treatment candidates that increase the lifespan of mice that model ALS.

11 Dec 2009

JMC receives NIH grant to establish center of excellence for autoimmune diseases

The Department of Neurology at Jefferson Medical College (JMC) of Thomas Jefferson University has been awarded a multi-million dollar grant from the National Institutes of Health (NIH) for the creation of a center of excellence to study autoimmune diseases from basic science research to its translation into clinical applications.

10 Dec 2009

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

AVANIR Pharmaceuticals, Inc. today announced additional data from the subset of patients with amyotrophic lateral sclerosis (ALS) enrolled in the confirmatory Phase III STAR trial.

9 Dec 2009

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Sangamo BioSciences, Inc. announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

9 Dec 2009

Sclerosis News and Research

Healthcare management application targeting MS patients released

TSC proteins regulate Notch activity

Nutrient-rich foods for weight loss

Senate health care bill will increase patient access and help create high-wage, high-value jobs

Study reveals genomic switches separate autoimmune disorders in different clusters

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

Researchers mix active drug and placebo to maximize drug benefits for efficient treatment

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

UAB professors honored for scientific contributions and outstanding mentorship

Opexa Therapeutics completes registered direct offering

People are more prone to Crohn's disease and ulcerative colitis, explains new research

EMD Serono, Brigham and Women's Hospital collaborate in MS research

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

UT researchers identify new molecule that slows ALS progression in mice

microRNA-206 plays crucial role in the progression of ALS

Prize4life partners with Jackson Laboratory on AML research

JMC receives NIH grant to establish center of excellence for autoimmune diseases

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News